keyword
https://read.qxmd.com/read/38405458/revolutionizing-cancer-treatment-unleashing-the-power-of-viral-vaccines-monoclonal-antibodies-and-proteolysis-targeting-chimeras-in-the-new-era-of-immunotherapy
#21
REVIEW
Popat Mohite, Vaishnavi Yadav, Ramdas Pandhare, Swastika Maitra, Fayez M Saleh, Rasha Mohammed Saleem, Hamdan S Al-Malky, Vinoth Kumarasamy, Vetriselvan Subramaniyan, Mohamed M Abdel-Daim, Daniel E Uti
In the realm of cancer immunotherapy, a profound evolution has ushered in sophisticated strategies that encompass both traditional cancer vaccines and emerging viral vaccines. This comprehensive Review offers an in-depth exploration of the methodologies, clinical applications, success stories, and future prospects of these approaches. Traditional cancer vaccines have undergone significant advancements utilizing diverse modalities such as proteins, peptides, and dendritic cells. More recent innovations have focused on the physiological mechanisms enabling the human body to recognize and combat precancerous and malignant cells, introducing specific markers like peptide-based anticancer vaccines targeting tumor-associated antigens...
February 20, 2024: ACS Omega
https://read.qxmd.com/read/38400885/intestinal-microbiota-modulates-the-antitumor-effect-of-oncolytic-virus-vaccines-in-colorectal-cancer
#22
JOURNAL ARTICLE
Xia Chen, Guanjun Wang, Ling Qin, Bing Hu, Jun Li
BACKGROUND: Immunotherapies, such as oncolytic viruses, have become powerful cancer treatments, but only some patients with cancer can benefit from them, especially those with advanced-stage cancer, and new therapeutic strategies are needed to facilitate extended survival. The intestinal microbiota may contribute to colorectal cancer (CRC) carcinogenesis and the response to immunotherapy. However, whether and how the intestinal microbiota modulates the effects of oncolytic virus vaccines (OVVs) in CRC remain to be investigated...
February 24, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38400597/sting-activator-2-3-cgamp-enhanced-hsv-1-based-oncolytic-viral-therapy
#23
JOURNAL ARTICLE
Patricia Angela Sibal, Shigeru Matsumura, Toru Ichinose, Itzel Bustos-Villalobos, Daishi Morimoto, Ibrahim R Eissa, Mohamed Abdelmoneim, Mona Alhussein Mostafa Aboalela, Nobuaki Mukoyama, Maki Tanaka, Yoshinori Naoe, Hideki Kasuya
Oncolytic viruses (OVs) can selectively replicate in tumor cells and remodel the microenvironment of immunologically cold tumors, making them a promising strategy to evoke antitumor immunity. Similarly, agonists of the stimulator of interferon genes (STING)-interferon (IFN) pathway, the main cellular antiviral system, provide antitumor benefits by inducing the activation of dendritic cells (DC). Considering how the activation of the STING-IFN pathway could potentially inhibit OV replication, the use of STING agonists alongside OV therapy remains largely unexplored...
February 23, 2024: Molecular Oncology
https://read.qxmd.com/read/38399429/a-review-of-current-and-pipeline-drugs-for-treatment-of-melanoma
#24
REVIEW
Nicole Natarelli, Sarah J Aleman, Isabella M Mark, Jasmine T Tran, Sean Kwak, Elizabeth Botto, Shaliz Aflatooni, Michael J Diaz, Shari R Lipner
Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is suitable for localized cases, sometimes involving lymph node dissection and biopsy, to assess the spread of the disease. Radiation therapy may be sometimes used as a standalone treatment or following surgical excision. Systemic chemotherapy, while having low response rates, is utilized as part of combination treatments or when other methods fail...
February 7, 2024: Pharmaceuticals
https://read.qxmd.com/read/38386514/combination-immunotherapy-of-oncolytic-flu-vectored-virus-and-pd-1-blockade-enhances-antitumor-activity-in-hepatocellular-carcinoma
#25
JOURNAL ARTICLE
Hongyu Yu, Fang Sun, Yan Xu, Hao Yang, Chongyu Tian, Cong Li, Yimin Kang, Lei Hao, Penghui Yang
BACKGROUND: Oncolytic viruses (OVs) have emerged as promising agents for antitumor therapy; however, their effectiveness remains limited. Our objective in this study was to enhance the antitumor efficacy of OVs by combining them with immune checkpoint inhibitors (ICIs). METHODS: Using reverse genetics technology, we developed a novel oncolytic influenza virus called delNS1-GM-CSF. Characterization of delNS1-GM-CSF included hemagglutination and TCID50 assays, followed by purification and observation of viral morphology using electron microscopy...
February 22, 2024: Human Gene Therapy
https://read.qxmd.com/read/38357194/yb-1-based-oncolytic-virotherapy-in-combination-with-cd47-blockade-enhances-phagocytosis-of-pediatric-sarcoma-cells
#26
JOURNAL ARTICLE
Anna Josefine von Ofen, Uwe Thiel, Jennifer Eck, Hendrik Gassmann, Melanie Thiede, Julia Hauer, Per Sonne Holm, Sebastian J Schober
Oncolytic viruses (OVs) selectively replicate in tumor cells resulting in lysis, spreading of new infectious units and induction of antitumor immune responses through abrogating an immunosuppressive tumor microenvironment (TME). Due to their mode of action, OVs are ideal combination partners with targeted immunotherapies. One highly attractive combination is the inhibition of the 'don't-eat-me'-signal CD47, which is known to increase the phagocytic potential of tumor-associated macrophages. In this work, we analyzed the combination approach consisting of the YB-1-based oncolytic adenovirus XVir-N-31 (XVir) and the CD47 inhibitor (CD47i) B6...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38336902/an-oncolytic-virus-t-cell-chimera-for-cancer-immunotherapy
#27
JOURNAL ARTICLE
Yuxuan Chen, Xiaohong Chen, Weier Bao, Gang Liu, Wei Wei, Yuan Ping
The efficacy of oncolytic adenoviruses (OAs) for cancer therapy has been limited by insufficient delivery to tumors after systemic injection and the propensity of OAs to induce the expression of immune checkpoints. To address these limitations, we use T cells to deliver OAs into tumors and engineer the OA to express a Cas9 system targeting the PDL1 gene encoding the immune checkpoint protein PD-L1. By cloaking OAs with cell membranes presenting T cell-specific antigens, we physically conjugated OAs onto T cell surfaces by antigen-receptor interaction...
February 9, 2024: Nature Biotechnology
https://read.qxmd.com/read/38328418/recombinant-newcastle-disease-viruses-expressing-immunological-checkpoint-inhibitors-induce-a-pro-inflammatory-state-and-enhance-tumor-specific-immune-responses-in-two-murine-models-of-cancer
#28
JOURNAL ARTICLE
Lisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, Robert C Mould, Jacob G E Yates, Thomas M McAusland, James J Petrik, Pierre P Major, Byram W Bridle, Sarah K Wootton
INTRODUCTION: Tumor microenvironments are immunosuppressive due to progressive accumulation of mutations in cancer cells that can drive expression of a range of inhibitory ligands and cytokines, and recruitment of immunomodulatory cells, including myeloid-derived suppressor cells (MDSC), tumor-associated macrophages, and regulatory T cells (Tregs). METHODS: To reverse this immunosuppression, we engineered mesogenic Newcastle disease virus (NDV) to express immunological checkpoint inhibitors anti-cytotoxic T lymphocyte antigen-4 and soluble programmed death protein-1...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38318175/tcr-transgenic-t-cells-and-yb-1-based-oncolytic-virotherapy-improve-survival-in-a-preclinical-ewing-sarcoma-xenograft-mouse-model
#29
JOURNAL ARTICLE
Sebastian J Schober, Melanie Thiede, Hendrik Gassmann, Anna Josefine von Ofen, Pia Knoch, Jennifer Eck, Carolin Prexler, Corazon Kordass-Wally, Julia Hauer, Stefan Burdach, Per Sonne Holm, Uwe Thiel
BACKGROUND: Ewing sarcoma (EwS) is an aggressive and highly metastatic bone and soft tissue tumor in pediatric patients and young adults. Cure rates are low when patients present with metastatic or relapsed disease. Therefore, innovative therapy approaches are urgently needed. Cellular- and oncolytic virus-based immunotherapies are on the rise for solid cancers. METHODS: Here, we assess the combination of EwS tumor-associated antigen CHM1319 -specific TCR-transgenic CD8+ T cells and the YB-1-driven (i...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38291394/pd-1-inhibitor-plus-oncolytic-vaccinia-virus-is-a-safe-and-effective-treatment-option-for-metastatic-renal-cell-carcinoma
#30
JOURNAL ARTICLE
Jee Soo Park, Myung Eun Lee, Jongchan Kim, Keunhee Oh, Namhee Lee, Minsun Jung, Won Sik Jang, Won Sik Ham
BACKGROUND: Although a combination of immune checkpoint inhibitors (ICIs) is recommended as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune-related adverse events (irAEs) occur, especially hepatitis. We explored the therapeutic benefits and safety profile of combining oncolytic vaccinia virus, JX-594, with a programmed cell death protein-1 (PD-1) inhibitor. METHODS: We used early-stage and advanced-stage orthotopic murine mRCC models developed by our group...
January 30, 2024: Cancer Cell International
https://read.qxmd.com/read/38279265/role-of-immunotherapy-in-sarcomas
#31
REVIEW
Shivani Dalal, Khine Swe Shan, Nyein Nyein Thaw Dar, Atif Hussein, Alejandra Ergle
Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has revolutionized the treatment of various solid and hematological malignancies. In this review, we discuss the basics of immunotherapy and the immune microenvironment in sarcomas; various modalities of immunotherapy, like immune checkpoint blockade, oncolytic viruses, cancer-targeted antibodies, vaccine therapy; and adoptive cell therapies like CAR T-cell therapy, T-cell therapy, and TCR therapy...
January 19, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38275827/overcoming-resistance-mechanisms-to-immune-checkpoint-inhibitors-leveraging-the-anti-tumor-immune-response
#32
REVIEW
Courtney H Coschi, Rosalyn A Juergens
As far back as 3000 years ago, the immune system was observed to play a role in mediating tumor regression. Since then, many strategies have been developed to leverage the anti-tumor immune response. However, while many patients respond to ICIs up front some do not, and many of those that do eventually experience tumor progression. Currently, there are several predictive biomarkers of the immune checkpoint inhibitor response; however, no one test appears to be universally predictive and their application varies by disease site...
December 19, 2023: Current Oncology
https://read.qxmd.com/read/38266449/novel-immunotherapies-for-breast-cancer-focus-on-2023-findings
#33
REVIEW
Huan-Rong Lan, Min Chen, Shi-Ya Yao, Jun-Xia Chen, Ke-Tao Jin
Immunotherapy has emerged as a revolutionary approach in cancer therapy, and recent advancements hold significant promise for breast cancer (BCa) management. Employing the patient's immune system to combat BCa has become a focal point in immunotherapeutic investigations. Strategies such as immune checkpoint inhibitors (ICIs), adoptive cell transfer (ACT), and targeting the tumor microenvironment (TME) have disclosed encouraging clinical outcomes. ICIs, particularly programmed cell death protein 1 (PD-1)/PD-L1 inhibitors, exhibit efficacy in specific BCa subtypes, including triple-negative BCa (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive cancers...
February 15, 2024: International Immunopharmacology
https://read.qxmd.com/read/38261838/cancer-immunotherapy-with-enveloped-self-amplifying-mrna-carg-2020-that-modulates-il-12-il-17-and-pd-l1-pathways-to-prevent-tumor-recurrence
#34
JOURNAL ARTICLE
Ju Chen, Bhaskara Reddy Madina, Elham Ahmadi, Timur Olegovich Yarovinsky, Marie Marthe Krady, Eileen Victoria Meehan, Isabella China Wang, Xiaoyang Ye, Elise Pitmon, Xian-Yong Ma, Bijan Almassian, Valerian Nakaar, Kepeng Wang
Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. Here, we describe the application of virus-like vesicles (VLV) for delivery of three immunomodulators alone and in combination, as a promising approach for cancer immunotherapy. VLV vectors were designed to deliver single chain interleukin (IL)-12, short-hairpin RNA (shRNA) targeting programmed death ligand 1 (PD-L1), and a dominant-negative form of IL-17 receptor A (dn-IL17RA) as a single payload or as a combination payload...
January 2024: Acta Pharmaceutica Sinica. B
https://read.qxmd.com/read/38254772/beyond-pd-l-1-blockade-in-microsatellite-instable-cancers-current-landscape-of-immune-co-inhibitory-receptor-targeting
#35
REVIEW
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, Gloria Pellizzari, Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Matteo Repetto, Carmen Belli, Giuseppe Curigliano
High microsatellite instability (MSI-H) derives from genomic hypermutability due to deficient mismatch repair function. Colorectal (CRC) and endometrial cancers (EC) are the tumor types that more often present MSI-H. Anti-PD(L)-1 antibodies have been demonstrated to be agnostically effective in patients with MSI-H cancer, but 50-60% of them do not respond to single-agent treatment, highlighting the necessity of expanding their treatment opportunities. Ipilimumab (anti-CTLA4) is the only immune checkpoint inhibitor (ICI) non-targeting PD(L)-1 that has been approved so far by the FDA for MSI-H cancer, namely, CRC in combination with nivolumab...
January 9, 2024: Cancers
https://read.qxmd.com/read/38251660/discussion-of-using-oncolytic-virus-to-retask-cd19-chimeric-antigen-receptor-t-cells-for-treatment-of-pancreatic-cancer-toward-a-universal-chimeric-antigen-receptor-t-cell-strategy-for-solid-tumor
#36
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 22, 2024: Journal of the American College of Surgeons
https://read.qxmd.com/read/38250045/-89-zr-cd8-immunopet-imaging-of-glioblastoma-multiforme-response-to-combination-oncolytic-viral-and-checkpoint-inhibitor-immunotherapy-reveals-cd8-infiltration-differential-changes-in-preclinical-models
#37
JOURNAL ARTICLE
Carlos A Gallegos, Yun Lu, Jennifer C Clements, Patrick N Song, Shannon E Lynch, Alessandro Mascioni, Fang Jia, Yolanda E Hartman, Adriana V F Massicano, Hailey A Houson, Suzanne E Lapi, Jason M Warram, James M Markert, Anna G Sorace
Rationale: Novel immune-activating therapeutics for the treatment of glioblastoma multiforme (GBM) have shown potential for tumor regression and increased survival over standard therapies. However, immunotherapy efficacy remains inconsistent with response assessment being complicated by early treatment-induced apparent radiological tumor progression and slow downstream effects. This inability to determine early immunotherapeutic benefit results in a drastically decreased window for alternative, and potentially more effective, treatment options...
2024: Theranostics
https://read.qxmd.com/read/38246780/-progress-in-the-treatment-of-soft-tissue-sarcoma-in-the-2023-annual-meeting-of-the-american-society-of-clinical-oncology
#38
JOURNAL ARTICLE
J L Zhao, W F Liu
Soft tissue sarcoma (STS) is a group of rare malignant tumors originating from mesenchymal tissue, with a high degree of malignancy and a wide range of pathological subtypes. The prognosis varies among different subtypes, and treatment increasingly relies on selecting appropriate treatment methods for different subtypes. Surgical treatment is still the main treatment method at present, and the development of immune and targeted therapy also brings new hope for the treatment of soft tissue sarcoma. Immune checkpoint inhibitors, oncolytic viruses and T cell therapy have shown well safety and efficacy in clinical trials...
January 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38243252/new-immunotherapy-approaches-for-colorectal-cancer-focusing-on-car-t-cell-bite-and-oncolytic-viruses
#39
REVIEW
Amin Kamrani, Hadi Nasiri, Ali Hassanzadeh, Javad Ahmadian Heris, Reza Mohammadinasab, Shahram Sadeghvand, Mohammadreza Sadeghi, Zahra Valedkarimi, Ramin Hosseinzadeh, Navid Shomali, Morteza Akbari
Colorectal cancer is one of the most common causes of mortality worldwide. There are several potential risk factors responsible for the initiation and progression of colorectal cancer, including age, family history, a history of inflammatory bowel disease, and lifestyle factors such as physical activity and diet. For decades, there has been a vast amount of study on treatment approaches for colorectal cancer, which has led to conventional therapies such as chemotherapy, surgery, etc. Considering the high prevalence and incidence rate, scholars believe there is an urgent need for an alternative, more efficacious treatment with fewer adverse effects than the abovementioned treatments...
January 19, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38242494/overview-of-tumor-immunotherapy-based-on-approved-drugs
#40
REVIEW
Ziqin Chen, Tiantian Hu, Jing Zhou, Xiaolei Gu, Song Chen, Qing Qi, Ling Wang
Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency...
January 17, 2024: Life Sciences
keyword
keyword
49467
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.